EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency

Paul E Constanthin iD, Nathalie Isidor, Sophie De Seigneux iD, Maria Mavromati, Mirjam Christ-Crain iD, Imane Lejri, Anne Eckert, Shahan Momjian iD

The Journal of Clinical Endocrinology & Metabolism · 18.11.2026 · 111 (12) · 3367-3375

DOI: 10.1210/clinem/dgag270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.07.2026. Verfasst von Paul E Constanthin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, 1205 Geneva, Switzerland. Hauptthemen laut MEDLINE: Oxytocin, Arginine Vasopressin, Postoperative Complications. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Foundation for medical-biological Research 2024, Fondation Ernst et Lucie Schmidheiny, SwissLife Jubiläumsstiftung für Volksgesundheit und medizinische Forschung 2024.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Arginine vasopressin deficiency (AVP-D) is a well-known complication of transsphenoidal pituitary surgery (TPS) that is difficult to predict because of the lack of specific biomarkers. Although oxytocin (OXT) and copeptin were previously suggested as possible biomarkers, there is, to date, no study that compared those 2 markers in the prediction of post-TPS AVP-D.

Objectives

To compare plasma OXT and copeptin levels among patients operated by TPS presenting with AVP-D and those remaining normonatremic. To establish OXT and copeptin cutoff values for the prediction of post-TPS AVP-D. Design and Patients Both OXT and copeptin levels in the blood of 74 consecutive patients subjected to TPS were measured. OXT and copeptin values were then compared between patients developing AVP-D and patients remaining normonatremic.

Setting

Neurosurgical department of a university hospital. Main outcome measures Blood levels of copeptin and OXT were measured before, 1 day after, and 3 months after TPS.

Results

Patients developing AVP-D showed significantly lower levels of OXT in blood, both before and immediately after TPS, and significantly lower levels of copeptin only after TPS. We identified a preoperative cutoff value for OXT of 69 pg/mL (sensitivity: 90%; specificity: 66%; area under the curve: 0.76 ± 0.06 [P = .0089]) for the prediction of AVP-D. No such significant cutoff values were identified for preoperative copeptin. Of note, OXT, but not copeptin, levels were still significantly lower at 3 months after TPS in AVP-D patients.

Conclusion

These results show for the first time that OXT is superior to copeptin for the preoperative prediction of postoperative AVP-D, acting as a preoperative marker of posterior “pituitary reserve.”

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxytocinArginine VasopressinPostoperative ComplicationsHumansFemaleGlycopeptidesMaleAdultMiddle AgedBiomarkersPredictive Value of TestsPituitary Neoplasms

Stichwörter der Autor:innen

arginine vasopressin deficiencycopeptinneurosurgeryoxytocinpituitary gland

Substanzen

OxytocinArginine VasopressincopeptinsGlycopeptidesBiomarkers

Autor:innen und Institutionen

  • Division of Neurosurgery, Department of Clinical Neurosciences, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland.
  • HUG NeuroCentre, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Department of Nephrology, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Department of Endocrinology, Diabetology, and Metabolism, Geneva University Hospitals, 1205 Geneva, Switzerland.
  • Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.

ORCID-Profile: Paul E Constanthin, Sophie De Seigneux, Mirjam Christ-Crain, Shahan Momjian

Förderung

  • Novartis Foundation for medical-biological Research 2024
  • Fondation Ernst et Lucie Schmidheiny
  • SwissLife Jubiläumsstiftung für Volksgesundheit und medizinische Forschung 2024
  • SwissLife Jubiläumsstiftung für Volksgesundheit und medizinische Forschung 2024

Zitieren

APA

Constanthin, P. E., Isidor, N., De Seigneux, S., Mavromati, M., Christ-Crain, M., Lejri, I., Eckert, A., & Momjian, S. (2026). Plasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency. The Journal of Clinical Endocrinology & Metabolism, 111(12), 3367-3375. https://doi.org/10.1210/clinem/dgag270

Vancouver

Constanthin PE, Isidor N, De Seigneux S, Mavromati M, Christ-Crain M, Lejri I, et al. Plasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency. The Journal of Clinical Endocrinology & Metabolism. 2026;111(12):3367-3375. doi:10.1210/clinem/dgag270

BibTeX
@article{Constanthin2026,
  author = {Constanthin, Paul E and Isidor, Nathalie and De Seigneux, Sophie and Mavromati, Maria and Christ-Crain, Mirjam and Lejri, Imane and Eckert, Anne and Momjian, Shahan},
  title = {Plasma oxytocin, early predictor of transient postoperative arginine vasopressin deficiency},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {12},
  pages = {3367--3375},
  doi = {10.1210/clinem/dgag270}
}
Kostenlos starten →